René Bruno

René Bruno

Auto-generated profile, based on publicly available information

René Bruno

Clinical Pharmacology, Genentech‐Roche Marseille France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LCLaurent Claret
Laurent Claret
PGPascal Girard
Pascal Girard
PHPaulo M. Hoff
Paulo M. Hoff
ECEric Van Cutsem
Eric Van Cutsem
KZKlaas P. Zuideveld
Klaas P. Zuideveld
RBRené Bruno
René Bruno
Purpose: We developed a drug-disease simulation model to predict antitumor response and overall survival in phase III studies from longitudinal tumor size data in phase II trials. Methods: We developed a longitudinal exposure-response tumor-growth inhibition (TGI) model of drug effect (and resistance) using phase II data of capecitabine (n = 34) and historical phase III data of fluorouracil (FU; n = 252) in colorectal cancer (CRC); and we developed a parametric survival model that related change in tumor size and patient characteristics to survival time using historical phase III data (n = 245). The models were validated in simulation of antitumor response and survival in an independent phase III study (n = 1,000 replicates) of capecitabine versus FU in CRC. Results: The TGI model provided a good fit of longitudinal tumor size data. A lognormal distribution best described the survival time, and baseline tumor size and change in tumor size from baseline at week 7 were predictors (P < .00001). Predicted change of tumor size and survival time distributions in the phase III study for both capecitabine and FU were consistent with observed values, for example, 431 days (90% prediction interval, 362 to 514 days) versus 401 days observed for survival in the capecitabine arm. A modest survival improvement of 39 days (90% prediction interval, −21 to 110 days) versus 35 days observed was predicted for capecitabine. Conclusion: The modeling framework successfully predicted survival in a phase III trial on the basis of capecitabine phase II data in CRC. It is a useful tool to support end-of-phase II decisions and design of phase III studies.

16 December 2016 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MSM Stroh
M Stroh
HWH Winter
H Winter
MMM Marchand
M Marchand
LCL Claret
L Claret
SES Eppler
S Eppler
SGS Girish
S Girish

10 June 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LCLaurent Claret
Laurent Claret
MGManish Gupta
Manish Gupta
KHKelong Han
Kelong Han
AJAmita Joshi
Amita Joshi
NSNenad Sarapa
Nenad Sarapa
RBRené Bruno
René Bruno
Purpose: To assess new metrics of tumor-size response to predict overall survival (OS) in colorectal cancer (CRC) in Western and Chinese patients. Patients and Methods: Various metrics of tumor-size response were estimated using longitudinal tumor size models and data from two phase III studies that compared bevacizumab plus chemotherapy versus chemotherapy as first-line therapy in Western (n = 923) and Chinese (n = 203) patients with CRC. Baseline prognostic factors and tumor-size metrics estimates were assessed in multivariate models to predict OS. Predictive performances of the models were assessed by simulating multiple replicas of the phase III studies. Results: Time to tumor growth (TTG) was the best metric to predict OS. TTG fully captured bevacizumab effect. Chinese ethnicity had no impact on OS or on the TTG-OS relationships. The model correctly predicted OS distributions in each arm as well as bevacizumab hazard ratio (model prediction, 0.75 v 0.68 observed in Western patients; 95% prediction interval, 0.62 to 0.91). Conclusion: TTG captured therapeutic benefit with bevacizumab in first-line CRC patients. Chinese ethnicity had no impact. Longitudinal tumor size data coupled with model-based approaches may offer a powerful alternative in the design and analysis of early clinical studies.

23 December 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RBRené Bruno
René Bruno
DBDean Bottino
Dean Bottino
DADinesh P. de Alwis
Dinesh P. de Alwis
AFAntonio T. Fojo
Antonio T. Fojo
JGJérémie Guedj
Jérémie Guedj
JJJin Y. Jin
Jin Y. Jin
There is a need for new approaches and endpoints in oncology drug development, particularly with the advent of immunotherapies and the multiple drug combinations under investigation. Tumor dynamics modeling, a key component to oncology “model-informed drug development,” has shown a growing number of applications and a broader adoption by drug developers and regulatory agencies in the past years to support drug development and approval in a variety of ways. Tumor dynamics modeling is also being investigated in personalized cancer therapy approaches. These models and applications are reviewed and discussed, as well as the limitations and issues open for further investigations. A close collaboration between stakeholders like clinical investigators, statisticians, and pharmacometricians is warranted to advance clinical cancer therapeutics.

21 September 2019 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
KMKari M. Morrissey
Kari M. Morrissey
MMMathilde Marchand
Mathilde Marchand
HPHina Patel
Hina Patel
RZRong Zhang
Rong Zhang
BWBenjamin Wu
Benjamin Wu
RBRené Bruno
René Bruno
Purpose: To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens. Methods: ER analyses were conducted using pooled NSCLC and UC data from phase 1 and 3 studies (PCD4989g, OAK, IMvigor211; ClinicalTrials.gov IDs, NCT01375842, NCT02008227, and NCT02302807, respectively). Objective response rate, overall survival, and adverse events were evaluated vs pharmacokinetic (PK) metrics. Population PK-simulated exposures for regimens of 840 mg every 2 weeks (q2w) and 1680 mg every 4 weeks (q4w) were compared with the approved regimen of 1200 mg every 3 weeks (q3w) and the maximum assessed dose (MAD; 20 mg/kg q3w). Phase 3 IMpassion130 (NCT02425891) data were used to validate the PK simulations for 840 mg q2w. Observed safety data were evaluated by exposure and body weight subgroups. Results: No significant ER relationships were observed for safety or efficacy. Predicted exposures for 840 mg q2w and 1680 mg q4w were comparable to 1200 mg q3w and the MAD and consistent with observed PK data from IMpassion130. Observed safety was similar between patients with a Cmax above and below the predicted Cmax for 1680 mg q4w and between patients in the lowest and upper 3 body weight quartiles. Conclusion: Atezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility.

13 January 2014 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
RBR Bruno
R Bruno
FMF Mercier
F Mercier
LCL Claret
L Claret